Arcellx (ACLX) Cash from Financing Activities (2021 - 2025)
Arcellx's quarterly Cash from Financing Activities came in at $1.6 million in Q4 2025, up 127.16% year-on-year from $719328.2 in Q4 2024, and down 98.1% quarter-over-quarter from $86.1 million in Q3 2025.
Arcellx has reported Cash from Financing Activities for 5 years, with the latest figure at $1.6 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 127.16% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $98.5 million (up 509.08% YoY), and the FY2025 full-year result was $98.5 million, up 509.08% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $1.6 million, down from $86.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $188.6 million in Q4 2023, with the low at -$10.4 million in Q2 2024.
- Average Cash from Financing Activities over 5 years is $36.2 million, with a median of $928500.0 recorded in 2022.
- Year-over-year, Cash from Financing Activities jumped 14252.44% in 2023 and slumped 9088.79% in 2024.
- Tracing ACLX's Cash from Financing Activities over 5 years: stood at $15000.0 in 2021, then soared by 8660.0% to $1.3 million in 2022, then jumped by 14252.44% to $188.6 million in 2023, then plunged by 103.19% to -$6.0 million in 2024, then soared by 127.16% to $1.6 million in 2025.
- The last three Cash from Financing Activities figures came in at $1.6 million (Q4 2025), $86.1 million (Q3 2025), and $10.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.63 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 86.10 Mn |
| Sep 30, 2025 | 86.10 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 543,000.00 |
| Mar 31, 2025 | 543,000.00 |
| Dec 31, 2024 | -6.02 Mn |
| Dec 31, 2024 | -6.02 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Mar 31, 2024 | -2.99 Mn |
| Dec 31, 2023 | 188.59 Mn |
| Dec 31, 2023 | 188.59 Mn |
| Sep 30, 2023 | -4.99 Mn |
| Sep 30, 2023 | -4.99 Mn |
| Jun 30, 2023 | 116,000.00 |
| Jun 30, 2023 | 116,000.00 |
| Mar 31, 2023 | 95.45 Mn |
| Mar 31, 2023 | 95.45 Mn |
| Dec 31, 2022 | 1.31 Mn |
| Dec 31, 2022 | 1.31 Mn |
| Sep 30, 2022 | -9.71 Mn |
| Sep 30, 2022 | -9.71 Mn |
| Jun 30, 2022 | 121.46 Mn |
| Jun 30, 2022 | 121.46 Mn |
| Mar 31, 2022 | 139.56 Mn |
| Mar 31, 2022 | 139.56 Mn |
| Dec 31, 2021 | 15,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | -467,000.00 |
| Sep 30, 2021 | -467,000.00 |
| Jun 30, 2021 | 37.28 Mn |
| Jun 30, 2021 | 37.28 Mn |
| Mar 31, 2021 | 81.63 Mn |
| Mar 31, 2021 | 81.63 Mn |